Artiva shuts down after two deaths in autoimmune cell therapy trial

Artiva Therapeutics is shutting down following two deaths in a clinical trial testing cell therapy for autoimmune disease, STAT News reported October 27. The report places the closure within a broader industry effort to adapt cancer treatment strategies, particularly engineered cell therapies, for use against autoimmune conditions.

According to STAT’s account, the fatal trial outcomes represent a significant setback for that effort. Cell therapies of this kind typically work by modifying a patient’s immune cells to target specific disease processes, an approach that has shown results in oncology and had drawn interest from drug companies seeking to extend it to autoimmune disorders.

The summary provided gives limited detail on the specific therapy, the trial’s design, or the circumstances of the two deaths. STAT’s reporting frames the closure as illustrative of risks facing companies attempting this translation from cancer treatment to autoimmune disease, rather than as an isolated single-company failure.

The item notes the deaths as a caution relevant to any effort at engineering immune responses, cancer-derived or otherwise, without elaborating further on mechanism, causality, or regulatory response. No additional detail on Artiva’s trial history, prior results, or the timeline leading to this outcome is included in the available material.

This bulletin reflects only the information contained in the cited STAT News report as summarized.